Brief: Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
30/12/2024 21:35
Dec 30 (Reuters) - Verastem Inc VSTM.O :
* VERASTEM ONCOLOGY ANNOUNCES FDA ACCEPTANCE AND PRIORITY
REVIEW
OF NEW DRUG APPLICATION FOR AVUTOMETINIB IN COMBINATION WITH
DEFACTINIB FOR THE TREATMENT OF RECURRENT KRAS MUTANT LOW-GRADE
SEROUS OVARIAN CANCER
* VERASTEM INC - PDUFA TARGET ACTION DATE SET FOR JUNE 30,
2025
Source text: ID:nBwBJ6h5a
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))